MedTrace Logo

Oxytocin Antagonist in Patients With Repeated Failure of Implantation

NCT01673399 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2021-02-02

No results posted yet for this study

Summary

In this study the investigators compare the usual way of embryo transfer (without medication) with an embryo transfer while administering oxytocine antagonist. This to improve implantation and increase the pregnancy rate.

Conditions

  • Implantation Failure

Interventions

DRUG

Atosiban

Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.

DRUG

placebo

Sponsors & Collaborators

  • Onze Lieve Vrouw Hospital

    collaborator OTHER

  • AZ Jan Palfijn Gent

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673399 on ClinicalTrials.gov